Basic Information
| LncRNA/CircRNA Name | GAS6-AS2 |
| Synonyms | NA |
| Region | GRCh38_13:113864168-113866833 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | Luciferase reporter assay, RIP, qPCR, Western blot, other |
| Sample | bladder cancer tissues and cell lines(SV-HUC-1, RT4, 5637, and T24) |
| Expression Pattern | up-regulated |
| Function Description | Further investigating the roles of GAS6-AS2, we found GAS6-AS2 regulated proliferation and proliferative activity of bladder cancer cells via inducing G1 phase arrest. What's more, we found that GAS6-AS2 contributed to metastatic abilities of cells. In mechanism, GAS6-AS2 could function as a competitive endogenous RNA (ceRNA) via direct sponging miR-298, which further regulating the expression of CDK9. Finally, we also proved that GAS6-AS2 knockdown suppressed tumour growth and metastasis in vivo. |
| Pubmed ID | 30394665 |
| Year | 2019 |
| Title | LncRNA GAS6-AS2 promotes bladder cancer proliferation and metastasis via GAS6-AS2/miR-298/CDK9 axis. |
External Links
| Links for GAS6-AS2 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |